Anzeige
Mehr »
Montag, 07.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1C017 | ISIN: FR0010907956 | Ticker-Symbol: CXT
Tradegate
04.07.25 | 21:48
0,630 Euro
-3,82 % -0,025
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
CARMAT Chart 1 Jahr
5-Tage-Chart
CARMAT 5-Tage-Chart
RealtimeGeldBriefZeit
0,5840,58710:17
0,6300,68004.07.

Aktuelle News zur CARMAT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoCARMAT Announces the Initiation of a Call for Public Tenders (Buyers or Investors) as Part of the Receivership Procedure285Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from...
► Artikel lesen
CARMAT Aktie jetzt für 0€ handeln
MiXFRA CXT: WIEDERAUFNAHME/RESUMPTION111FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
DiCarmat files for insolvency6
DiCARMAT Announces Its Placement in Receivership Procedure205Resumption of CARMAT shares trading starting July 2, 2025, at stock market opening Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial...
► Artikel lesen
30.06.XFRA CXT: AUSSETZUNG/SUSPENSION142DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCARMAT EO -,04 CXT...
► Artikel lesen
30.06.CARMAT Announces Filing Today for Insolvency and Requesting Being Placed in Receivership319Suspension of CARMAT shares trading starting June 30, 2025, before stock market opening Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total...
► Artikel lesen
24.06.Carmat is running out of cash5
20.06.In a Context of Critical Financial Situation, CARMAT Launches a Donation Campaign Open to All to Contribute to Its Funding and Continuation of Its Activities325Risk of insolvency as early as end of June 2025 Launch of a donation campaign open to all via the onparticipe.fr online platform To listen to CARMAT CEO's message, click here Regulatory...
► Artikel lesen
20.06.CARMAT Announces Being in a Critical Financial Situation and at Risk of Insolvency as of End-June 2025374Immediate need to secure approximately €3.5 million to avoid insolvency at the end of June 2025 Total funding needs of around €35 million over the next 12 months Ongoing active exploration...
► Artikel lesen
02.06.CARMAT Announces the First Commercial Implants of Its Aeson Artificial Heart Outside the European Union324Two implants have recently been performed in Israel Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide...
► Artikel lesen
12.05.CARMAT Completes Enrolment in the EFICAS Clinical Study and Receives Approval From French Authorities for 21 Additional Aeson Implants, While Awaiting Potential Reimbursement of the Device in France269Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from...
► Artikel lesen
30.04.CARMAT: Availability of the 2024 Universal Registration Document358Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from...
► Artikel lesen
29.04.CARMAT Announces Its 2024 Annual Results438Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from...
► Artikel lesen
14.04.CARMAT Receives FDA Conditional Approval to Initiate the Second Cohort of the EFS Study in the United States283Recruitment of the second cohort expected to begin in H2 2025 Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming...
► Artikel lesen
09.04.CARMAT Delivers Q1 2025 Results in Line With Its Objectives279Quarterly sales of €2.4m multiplied by 2.4 vs Q1 2024 EFICAS clinical trial recruitment 94% complete 2 scientific publications a strong driver of Aeson® adoption Final stage...
► Artikel lesen
03.04.CARMAT - Publication in the JACC(1): Heart Failure of the Initial Clinical Experience with Aeson Total Artificial Heart in Cardiogenic Shock Patients Initially Placed on Extracorporeal Life Support320The retrospective analysis on 10 patients shows a 90% survival rate at 6 months, suggesting Aeson® as a therapeutic solution for these patients at risk of death in the short term. Regulatory News: CARMAT...
► Artikel lesen
31.03.CARMAT to Provide a Business Update and Host a Videoconference on April 9, 2025306Please register to the videoconference by clicking on one of the following links: Videoconference in French at 6:00 pm CEST - Videoconference in English at 8:00 pm CEST Regulatory News: CARMAT...
► Artikel lesen
27.03.CARMAT announces the implementation of a flexible equity financing line with IRIS Capital Investment412Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from...
► Artikel lesen
17.02.CARMAT: Aeson total artificial heart highlighted as a very promising solution for heart failure patients with pulmonary hypertension in The Journal of Heart and Lung Transplantation542Up to 25% of advanced heart failure patients suffer from pulmonary hypertension Aeson® could potentially become a standard treatment for these thousands of patients, both as a bridge-to-transplant...
► Artikel lesen
10.02.CARMAT Achieves the Milestone of 100 Implants of Its Aeson Total Artificial Heart379Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from...
► Artikel lesen
Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3